Hitting tumors

at their

Achilles heel

Our Focus

Eisbach develops novel medicines that target chromatin regulatory mechanisms essential to tumors.

Our novel targets and best-in-class drug discovery allow us to develop a pipeline of impactful medicines.

Our Science

A Bold Approach

A tumor's genome constantly evolves. This makes tumors incredibly difficult to target.
We identified the engines that drive all genome rearrangements in tumors.
Our unique screening and cellular platforms are generating first-in-class inhibitors that allow us to directly target the key vulnerability present in genetically-defined tumors.

Our Clinical Goal

Treating Smartly

Specific tumors have specific biological requirements.
Our targets are essential in these genetically-defined tumors.
Our inhibitors thus target tumor cells in a highly specific and personalised manner.
By leveraging epigenetic mechanisms, we can now address unmet clinical needs.

We strive for better cures

Now is the time to leverage
the power of genomics
to develop the right drugs
for the right patients.

Tumor AI

Tumors harbor genetic fingerprints that reveal their Achilles heel

Best assays

Physiological assays identify drugs that hit this weak spot

Patient choice

Highly-specific drugs
for defined patient populations

Our Management Team

In our team we combine proprietary scientific knowledge of our target enzymes, in-depth understanding of drug discovery and broad executive experience

Adrian Schomburg

CEO

Co-Founder
Adrian Schomburg, PhD, is a drug discovery expert with over 10 years of experience in pharma and biotech. He moved projects successfully through drug discovery - from target identification to the delivery of preclinical and development candidates. In his former roles at Pfizer and Proteros, he kick-started collaborative R&D projects in epigenetics with big pharma.

Andreas Ladurner

CSO

Co-Founder
Prof. Andreas Ladurner, PhD, is a globally recognized expert in chromatin biology and metabolism. His pioneering discoveries include the discovery of bromodomain and macrodomain function, including the allosteric regulation of key epigenetic enzymes. He is Chair and Full Professor of Physiological Chemistry at the LMU in Munich.

News and Press Coverage

2022
January
Eisbach Bio announces a collaboration with the University of Texas MD Anderson Cancer Center to develop medicines targeting epigenetic machinery in oncology
2021
October
Eisbach Bio receives €6.7M grant from the Bavarian Government for the development of targeted SARS-CoV-2 antivirals
September
Collaboration with Technische Universität Kaiserslautern to develop sustainable COVID-19 inhibitors
July
BMBF announced 8 million EUR funding for COVID-19 antiviral clinical development
April
Eisbach Bio receives government grant to progress COVID-19 antiviral through Phase I/II clinical development
March
Collaboration with the Core Facility Animal Models BMC to test SARS-CoV-2 antivirals
2020
December
Coaxing cancer cells to commit suicide - Recent collaboration with the LMU
September
Video Interview for Reuters TV
August
Article in ZDF-Heute
July
Interview for Süddeutsche Zeitung
April
Eisbach joins worldwide efforts to combat COVID-19
January
Eisbach presented at BIOTECH SHOWCASE™ 2020 in San Francisco
2019
November
1st Prize Winner Startup Slam at BioEurope 2019
October
1st Prize Rising Stars Award at the BioEntrepreneurship Summit
June
Winner of the EIT Health Germany Headstart Awards 2019
BioM press release on Eisbach Bio
April
Eisbach is now eligible for the INVEST funding programme of the BMWi.
January
Moved into incubator lab space at the Ludwig-Maximilians-Universität Munich
2018
July
1st Prize Winner of the BioM Bio Entrepreneur Boot Camp 2018

Let's treat cancer smarter

Learn More

We are supported by:

EIT logo accelerated
INVEST_Logo_URL_rote_URL_RZ
BMBF_CMYK_Gef_M [Konvertiert]